Regulatory Affairs
Shane McGann joined Atavistik Bio as Vice President, Regulatory Affairs in January 2026. He oversees all aspects of regulatory affairs and medical writing, leading the regulatory strategy, preparation, and execution for all global Regulatory submissions, health authority interactions, and other key regulatory milestones across drug development. Shane brings with him nearly 15 years of biopharmaceutical industry and leadership experience. Prior to Atavistik, Shane spent time at Mythic Therapeutics, BridgeBio, and Agios Pharmaceuticals, where he held positions of increasing responsibility and led global regulatory strategic planning and execution across oncology and rare disease portfolios, spanning all stages of clinical development. In addition, while at Agios he was a Director and Preceptor for their Biopharmaceutical Industry Fellowship Program. Shane completed a post-doctoral Regulatory Affairs Fellowship at Genzyme, in conjunction with Massachusetts College of Pharmacy and Health Sciences, where he also served as adjunct faculty. During his career, Shane has led, overseen, and contributed to the regulatory strategy for numerous preclinical and clinical drug development programs, including ivosidenib (TIBSOVO®), vorasidenib (VORANIGO®), and infigratinib (TRUSELTIQ®).
He is a licensed pharmacist and received his Doctor of Pharmacy from Albany College of Pharmacy and Health Sciences, where he is a Member of their Board of Trustees.